Effect of Different Injection Regimens of Autologous Conditioned Plasma for Knee Osteoarthritis
| Status: | Recruiting |
|---|---|
| Conditions: | Arthritis, Osteoarthritis (OA) |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 30 - 80 |
| Updated: | 3/29/2019 |
| Start Date: | March 15, 2019 |
| End Date: | March 2021 |
| Contact: | Hillary Plummer, PhD |
| Email: | hillary.plummer@andrewsref.org |
| Phone: | 850-916-8796 |
Effect of Different Injection Regimens of Autologous Conditioned Plasma for the Treatment of Symptomatic Knee Osteoarthritis
The clinical efficacy of hyaluronic acid or corticosteroid injections has been reported, but
effects are short lived. This has led to the development of additional injection options such
as autologous derived blood products which have been documented to alleviate symptoms related
to knee osteoarthritis, with recent comparative studies suggesting a greater, long-lasting
effect with these blood derived products like platelet rich plasma (PRP) [2-8]. One
clinically-developed preparation of platelet rich plasma, named autologous conditioned plasma
(ACP), has randomized controlled trial data proving efficacy [4,9]. Clinical use of platelet
rich plasma for knee arthritis typically involves a 3-injection series over 3 weeks, i.e. an
injection once a week for three weeks. The main objective of this study is to determine if
hyaluronic acid (HA) injected at the same time as autologous conditioned plasma (ACP), a
leukocyte-poor platelet rich plasma product, will improve the performance of ACP in the
treatment of symptomatic knee osteoarthritis. It is hypothesized that the injection of
hyaluronic acid will improve the efficacy of ACP.
effects are short lived. This has led to the development of additional injection options such
as autologous derived blood products which have been documented to alleviate symptoms related
to knee osteoarthritis, with recent comparative studies suggesting a greater, long-lasting
effect with these blood derived products like platelet rich plasma (PRP) [2-8]. One
clinically-developed preparation of platelet rich plasma, named autologous conditioned plasma
(ACP), has randomized controlled trial data proving efficacy [4,9]. Clinical use of platelet
rich plasma for knee arthritis typically involves a 3-injection series over 3 weeks, i.e. an
injection once a week for three weeks. The main objective of this study is to determine if
hyaluronic acid (HA) injected at the same time as autologous conditioned plasma (ACP), a
leukocyte-poor platelet rich plasma product, will improve the performance of ACP in the
treatment of symptomatic knee osteoarthritis. It is hypothesized that the injection of
hyaluronic acid will improve the efficacy of ACP.
Inclusion Criteria:
- Patients between the ages of 30 and 80
- Documented radiographic evidence of OA in the tibiofemoral or patellofemoral
compartment of the involved knee (Kellgren-Lawrence grades 1-4)
- Patients must have a documented diagnosis of primary OA for at least 6 weeks.
Exclusion Criteria:
- Patients who have had viscosupplementation in the involved knee in the past 6 months.
- Any patient who has had a corticosteroid injection in any joint within 3-months prior
to screening will be excluded.
- Patients with gout or rheumatologic disease will be excluded. Patients who have had a
previous negative experience with HA.
- Any patient who will have difficulty obtaining internet access, does not have an
active e-mail address, or is unable to comprehend study documents or give informed
consent will be excluded.
We found this trial at
1
site
Gulf Breeze, Florida 32561
Principal Investigator: Adam Anz, MD
Phone: 850-916-8796
Click here to add this to my saved trials
